FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Dont Wait for SBOM Finalization: Fu

Former CDRH cybersecurity acting director Kevin Fu says the best companies are already submitting software bills of materials with their 510(k) and PM...

latest-news-card-1
Human Drugs

Hikma Injectables Hit With 3-item FDA-483

A recent inspection at Hikma Injectables USA results in a three-item Form FDA-483.

latest-news-card-1
Medical Devices

Breakthrough Device Guidance Updates

FDA publishes a draft guidance on proposed updates to an earlier breakthrough devices program guidance.

latest-news-card-1
Medical Devices

FDA Nixes Post-marketing Requirements on Impella Pumps

FDA closes its post-approval study requirements for Abiomed PMAs for its Impella heart pumps after reviewing favorable performance data.

latest-news-card-1
Human Drugs

FDA Launches Advancing RWE Program

FDA launches its Advancing Real-World Evidence Program intended to improve the quality and acceptability of real-world evidence approaches proposed by...

latest-news-card-1
Federal Register

FDA Extends Novel Trial Design Meeting Program

Federal Register notice: FDA announces that it is continuing a meeting program to advance the use of complex adaptive, Bayesian, and other novel clini...

latest-news-card-1
Human Drugs

PTC Says Huntingdons Trial Paused in the U.S.

PTC Therapeutics says enrollment in its Phase 2 Huntingdons disease trial has been paused in the U.S. due to an FDA request for additional data.

latest-news-card-1
Medical Devices

Philips Mask Recall is Class 1

FDA says the 8/2 Philips Respironics recall of certain BiPAP and CPAP masks is Class 1.

latest-news-card-1
Medical Devices

UDI Enforcement Policy, Alternatives FAQs

FDA posts frequently asked questions on UDI enforcement policy that changes with devices labeled on or after 9/24/23.

latest-news-card-1
Human Drugs

FDA Panel Shoots Down Makenas Continued Availability

An FDA advisory committee votes 14 to 1 to recommend the market withdrawal of Covis Makena (hydroxyprogesterone caproate injection, 250 mg/mL, once we...